RecruitingPhase 4NCT02347111

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs

Sponsor

University of Illinois at Chicago

Enrollment

162 participants

Start Date

Dec 31, 2020

Study Type

INTERVENTIONAL

Conditions

Atrial Fibrillation

Summary

In this pilot and feasibility study, the investigators will enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common AF genetic risk allele modulates response to different AADs.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying whether a patient's genetic makeup can predict which heart rhythm medication (flecainide or sotalol) will work best for controlling atrial fibrillation — an irregular heartbeat. **You may be eligible if...** - You are 18 or older - You have a history of paroxysmal or persistent atrial fibrillation (AF) — an irregular heartbeat — with at least 2 episodes per month - Your AF was confirmed on an ECG (heart tracing) within the past month - You are medically eligible to take both flecainide and sotalol **You may NOT be eligible if...** - You have permanent atrial fibrillation or only atrial flutter - You had heart or chest surgery in the last 6 months - You have previously taken amiodarone long-term - You have a serious illness expected to be fatal within a year - You have certain other heart conditions that make these medications unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.